DK1824504T3 - Anti-tumor-kombinationer, der indeholder VEGF-trap og 5-fluoruracil eller et derivat deraf - Google Patents

Anti-tumor-kombinationer, der indeholder VEGF-trap og 5-fluoruracil eller et derivat deraf

Info

Publication number
DK1824504T3
DK1824504T3 DK05824581T DK05824581T DK1824504T3 DK 1824504 T3 DK1824504 T3 DK 1824504T3 DK 05824581 T DK05824581 T DK 05824581T DK 05824581 T DK05824581 T DK 05824581T DK 1824504 T3 DK1824504 T3 DK 1824504T3
Authority
DK
Denmark
Prior art keywords
fluorouracil
derivative
vegf trap
combinations containing
containing vegf
Prior art date
Application number
DK05824581T
Other languages
English (en)
Inventor
Eric Furfine
Jocelyn Holash
Jesse M Cedarbaum
Patricia Vrignaud
Marielle Chiron-Blondel
Marie-Christine Bissery
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34954452&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1824504(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of DK1824504T3 publication Critical patent/DK1824504T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK05824581T 2004-12-03 2005-12-02 Anti-tumor-kombinationer, der indeholder VEGF-trap og 5-fluoruracil eller et derivat deraf DK1824504T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0412870A FR2878749B1 (fr) 2004-12-03 2004-12-03 Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
PCT/FR2005/003005 WO2006059012A1 (fr) 2004-12-03 2005-12-02 Combinaisons antitumorales contenant un agent inhibiteur de vegf et du 5fu ou un de ses derives

Publications (1)

Publication Number Publication Date
DK1824504T3 true DK1824504T3 (da) 2009-07-20

Family

ID=34954452

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05824581T DK1824504T3 (da) 2004-12-03 2005-12-02 Anti-tumor-kombinationer, der indeholder VEGF-trap og 5-fluoruracil eller et derivat deraf

Country Status (26)

Country Link
US (3) US20060178305A1 (da)
EP (1) EP1824504B1 (da)
JP (1) JP4980236B2 (da)
KR (1) KR101313404B1 (da)
CN (1) CN101068564B (da)
AT (1) ATE426409T1 (da)
AU (1) AU2005311191C1 (da)
BR (1) BRPI0518700B8 (da)
CA (1) CA2586735C (da)
CY (3) CY1109181T1 (da)
DE (1) DE602005013568D1 (da)
DK (1) DK1824504T3 (da)
ES (1) ES2324233T3 (da)
FR (1) FR2878749B1 (da)
HK (1) HK1114769A1 (da)
HR (1) HRP20090336T1 (da)
IL (1) IL183481A (da)
LU (2) LU92202I2 (da)
ME (1) ME01706B (da)
MX (1) MX2007006607A (da)
PL (1) PL1824504T3 (da)
PT (1) PT1824504E (da)
RS (1) RS50769B (da)
RU (1) RU2384344C2 (da)
SI (1) SI1824504T1 (da)
WO (1) WO2006059012A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2918279B1 (fr) * 2007-07-05 2010-10-22 Aventis Pharma Sa Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
JO3283B1 (ar) * 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
MA40354A (fr) 2014-07-18 2017-05-24 Sanofi Sa Procédé permettant de prédire le résultat d'un traitement avec de l'aflibercept d'un patient suspecté de souffrir d'un cancer
CN108712911A (zh) 2015-12-30 2018-10-26 科达制药股份有限公司 抗体及其缀合物
EP3246029A1 (en) * 2016-05-19 2017-11-22 Boehringer Ingelheim International Gmbh Pharmaceutical combination of nintedanib and capecitabine for the treatment of colorectal cancer
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
CN115197948A (zh) * 2021-04-13 2022-10-18 江苏康缘瑞翱生物医药科技有限公司 一种重组新城疫病毒rNDV-VEGF-Trap、其基因组、制备方法及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
ATE293164T1 (de) * 1999-06-08 2005-04-15 Regeneron Pharma Modifizierte chimärische polypeptide mit verbesserten pharmakokynetischen eigenschaften
AR046510A1 (es) * 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo

Also Published As

Publication number Publication date
RU2007123607A (ru) 2009-01-10
ME01706B (me) 2010-08-31
JP2008521866A (ja) 2008-06-26
US20090285841A1 (en) 2009-11-19
BRPI0518700B8 (pt) 2021-05-25
WO2006059012A1 (fr) 2006-06-08
AU2005311191A1 (en) 2006-06-08
BRPI0518700A2 (pt) 2008-12-02
CA2586735C (fr) 2014-08-12
US20060178305A1 (en) 2006-08-10
RU2384344C2 (ru) 2010-03-20
ES2324233T3 (es) 2009-08-03
AU2005311191C1 (en) 2015-04-30
MX2007006607A (es) 2007-07-25
IL183481A (en) 2013-09-30
BRPI0518700B1 (pt) 2020-02-11
US20130184205A1 (en) 2013-07-18
RS50769B (sr) 2010-08-31
LU92203I2 (fr) 2013-11-15
IL183481A0 (en) 2007-09-20
FR2878749A1 (fr) 2006-06-09
EP1824504A1 (fr) 2007-08-29
AU2005311191B2 (en) 2011-12-08
SI1824504T1 (sl) 2009-08-31
US8388963B2 (en) 2013-03-05
DE602005013568D1 (de) 2009-05-07
KR101313404B1 (ko) 2013-10-01
LU92202I9 (da) 2019-01-15
KR20070091130A (ko) 2007-09-07
CY1109181T1 (el) 2014-07-02
CY2013018I1 (el) 2020-05-29
FR2878749B1 (fr) 2007-12-21
CN101068564B (zh) 2010-12-15
PL1824504T3 (pl) 2009-08-31
HRP20090336T1 (en) 2009-07-31
LU92202I2 (fr) 2013-11-15
CY2013017I1 (el) 2014-07-02
ATE426409T1 (de) 2009-04-15
JP4980236B2 (ja) 2012-07-18
LU92203I9 (da) 2019-01-15
HK1114769A1 (en) 2008-11-14
CN101068564A (zh) 2007-11-07
CA2586735A1 (fr) 2006-06-08
PT1824504E (pt) 2009-06-25
EP1824504B1 (fr) 2009-03-25

Similar Documents

Publication Publication Date Title
DK1824504T3 (da) Anti-tumor-kombinationer, der indeholder VEGF-trap og 5-fluoruracil eller et derivat deraf
CY1119810T1 (el) Παραγωγα(2s,3r,4r,5s,6r)-2-(4-χλωρο-3-βενζυλφαινυλ)-6-(υδροξυμεθυλ)τετραϋδρο-2h-πυραν-3,4,5-τριολης για χρηση στη θεραπεια του διαβητη
CY1107440T1 (el) Ενωσεις αρυλουριας εν συνδυασμω με αλλα κυτταροστατικα ή κυτταροτοξικα μεσα για τη θεραπεια ανθρωπινων καρκινων
NO20055894L (no) Fremgangsmater og blandinger for behandling av amyloidrelatertere sykdommer
CL2007001996A1 (es) Compuestos derivados de heteroarilos nitrogenados sustituidos con fenilo, inhibidores de la produccion de citoquinas; composicion farmaceutica que los comprende; y sus usos en el tratamiento del cancer, infecciones, enfermedades inflamatorias y autoinmunes.
CY1113166T1 (el) Αναστολεις των ενζυμων ενεργοποιησης ε1
ECSP088329A (es) Nuevos diazaespiroalcanos y su uso para el tratamiento de enfermedades mediadas por ccr8
CY1111121T1 (el) Ετεροαρυλο ενωσεις χρησιμες ως αναστολεις ενζυμων ενεργοποiησης ε1
ATE517872T1 (de) Fünfgliedrige p38-kinaseinhibitoren auf heterocyclusbasis
NO20062420L (no) Anvendelse av IAP-oligomer og et kjemoterapeutisk middel for behandling av proliferative sykdommer
ATE499098T1 (de) Verwendung von parp-1-hemmern
UY31314A1 (es) Amidas heterociclicas y sus métodos de uso-976
CY1112383T1 (el) Αναστολεις της πρωτεϊνης ενεργοποιησης της 5-λιποξυγενασης (flap)
ATE489371T1 (de) Benzamidglucokinaseaktivatoren
NO20070580L (no) Behandling av cancer.
CL2007001748A1 (es) Compuesto derivado de 2-arilamino-4-aminopirimidinas, inhibidores de la proteina quinasa c-alfa; composiciones farmaceuticas que los contienen; y su uso para tratar o prevenir la diabetes, el cancer, enfermedades cardiovasculares y otras.
NO20076663L (no) Immunoglobuliner
DE602005010844D1 (de) Pharmazeutische zusammensetzungen mit interferon-tau
TW200716561A (en) P38 inhibitors and methods of use thereof
SE0300457D0 (sv) Novel compounds
NO20054723L (no) Behandling av proliferative sykdommer med epofilonderivater og straling
ATE478847T1 (de) Substituierte pyridylmethylbicyclocarboxyamidverbindungen
NO20075690L (no) Avlevering av tigesyklin i naervaer av heparin
EA202090234A1 (ru) СРЕДСТВА РНКи ДЛЯ ИНГИБИРОВАНИЯ ЭКСПРЕССИИ АЛЬФА-ENaC И СПОСОБЫ ПРИМЕНЕНИЯ
DK1888100T3 (da) Anvendelse af IL-18BP-isoformer til behandling og/eller forebyggelse af neurologiske inflammatoriske sygdomme